Quarterly Revenue and Consensus Outperformance
Q1 revenue was $19.8M, and management stated the quarter exceeded consensus estimates on both top and bottom lines, despite YoY revenue decline.
Adjusted EBITDA Expansion
Adjusted EBITDA rose to $3.3M in Q1 2026 from $1.5M in Q1 2025, an increase of approximately 120%, reflecting improved operating leverage and margin optimization.
Non-GAAP Profitability Improvement
Non-GAAP net income increased to $2.7M ($0.14 diluted) from $1.5M ($0.08) year-over-year (≈80% increase). GAAP net loss narrowed to $0.5M from $2.2M in the prior year quarter.
Strong Product Momentum — DAP Growth
AI-enabled DAP solution grew 60% year-over-year in Q1, with DAP subscription revenue up 45%, indicating accelerating product-market fit and greater subscription mix for revenue visibility.
Gross Margin and Expense Improvements
Company now expects full-year gross margin in the high 60% range. Total expenses decreased by $4.6M YoY (driven by lower cost of revenue and G&A). Management expects cash operating expense reductions of ~$3M annualized, including ~$1M in-year benefit for 2026.
Key Operating KPIs and Revenue Productivity
Net revenue retention remained strong at 110%. Revenue per FTE improved to $801K from $710K in Q1 2025 (≈12.8% increase). Average revenue per top-20 pharmaceutical manufacturer stands at $2.8M; top-20 accounted for 52% of Q1 revenue.
Balance Sheet and Financing Improvement
Refinanced term loan to Fifth Third Bank with a fully drawn $25M term loan and access to a $10M revolver. Management cites approximately $1.5M in expected annual interest expense savings from the refinance.
Programmatic / DSP Opportunity
Company is enabling demand-side platforms that control >80% of digital promotional dollars into its EHR network, estimating current utilization of <10% of inventory and positioning programmatic as a potential long-term growth channel with meaningful upside.